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Edited by Ivan SadowskiAbstract Human Topors has originally been identiﬁed as bind-
ing partner of p53 and DNA topoisomerase I (TOP1). It can
function as both an ubiquitin and SUMO-1 E3 ligase for p53.
Here we demonstrate that Topors enhances the formation of
high-molecular weight SUMO-1 conjugates of TOP1 in a recon-
stituted in vitro system and also in human osteosarcoma cells,
similar to treatment with CPT. In contrast to the situation ob-
served with p53, overall sumoylation levels were rather unaf-
fected. Experiments with TOP1 point mutants strongly suggest
that the high-molecular weight conjugates represent SUMO-1
chains formed on a limited number of SUMO-1 acceptor sites.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Human SUMO-1 (the small ubiquitin-like modiﬁer 1) is
covalently attached as a post-translational modiﬁcation to a
variety of cellular target proteins. After activation by the hete-
rodimeric E1 enzyme Aos-1/Uba2 and formation of a thioester
with the E2 conjugating enzyme ubiquitin conjugating enzyme
9 (UBC9), SUMO-1 is attached to speciﬁc lysine residues with-
in the target protein [1]. UBC9 physically interacts with many
known SUMO-1 substrates and the E1 and E2 enzymes are suf-
ﬁcient for SUMO-1 modiﬁcation of a variety of these substrates
in reconstituted systems. However, several diﬀerent types of
SUMO-1 E3 ligases such as the protein inhibitors of activated
STAT (PIAS) protein family, the nucleoporin RanBP2 or the
Polycomb protein Pc2, which stimulate the SUMO-1 sumoyla-
tion of speciﬁc substrates, have been identiﬁed [2]. Sumoylation
has been implicated in various functions such as regulation of
the stability, the intracellular localization and the transcrip-
tional activity of the respective target protein [3].
Human DNA topoisomerase I (TOP1) is a major SUMO-1
target in cells treated with the TOP1-speciﬁc camptothecin
(CPT) class of anticancer agents [4]. TOP1 catalyzes the relax-Abbreviations: SUMO, small ubiquitin-like modiﬁer; UBC9, ubiquitin
conjugating enzyme 9; GST, glutathione S-transferase; GFP, green
ﬂuorescent protein; YFP, yellow ﬂuorescent protein; PIAS, protein
inhibitors of activated STAT; HU, hydroxy-uracil
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doi:10.1016/j.febslet.2007.10.040ation of torsional stress associated with DNA replication,
recombination, transcription and chromatin condensation [5].
It transiently cleaves one strand of the double helix, creating
a protein-linked nick, which allows rotation of the other strand,
followed by religation of the phosphate backbone [5]. CPT and
its derivates reversibly stabilize the covalent TOP1-DNA inter-
mediate [6] accompanied by a rapid relocalization of TOP1
from the nucleolus to the nucleoplasm [7]. The hypersumoyla-
tion of TOP1 observed after treatment with CPT and experi-
ments with sumoylation-deﬁcient TOP1 mutants suggested an
involvement of TOP1 sumoylation in its partitioning between
the nucleoli and the nucleoplasm [8,9]. However, this issue re-
mains controversial in view of a more recent report concluding
that sumoylation does not aﬀect CPT-induced TOP1 relocaliza-
tion [10]. TOP1 sumoylation sites have been mapped to lysine
residues K103, K117 and K153 in the N-terminal part of the
protein, with K117 as the major acceptor site [9]. The existence
of polymeric SUMO-1 chains (polysumoylation) has long been
debated. However, polysumoylation has been demonstrated
in vitro for several substrates including a glutathione S-trans-
ferase (GST) fusion protein harboring only the region sur-
rounding the major TOP1 acceptor site at amino acid 117 [11].
Topors is a cellular RING ﬁnger protein, which binds to the
N-terminus of DNA topoisomerase I [12] and also to p53 [13].
While normally located in nuclear speckles closely associated
with the PML oncogenic domains (PODs) [14,15], it rapidly
relocalizes to the nucleoplasm after CPT treatment [14]. It pos-
sesses both RING ﬁnger dependent ubiquitin [16] and RING
ﬁnger independent SUMO-1 E3 ligase activities for p53 [17].
The drosophila homologue dTopors interacts with and directs
the nuclear organization of the gypsy chromatin insulator
complex [18]. Whereas this process involves sumoylation of
Mod(mdg4)2.2 and Cp190, dTopors does not seem to directly
function as a SUMO-1 E3 ligase for these proteins [19].
In the present study we demonstrate a Topors induced accu-
mulation of high-molecular weight SUMO-1 conjugates of
TOP1 both in a reconstituted in vitro sumoylation system
and in vivo. Point mutations of the TOP1 SUMO-1 acceptor
sites show that these high-molecular weight forms are most
likely due to polysumoylation at a very limited number of
lysine residues.2. Materials and methods
2.1. Plasmid construction
Plasmid pBS-Top1 for in vitro transcription/translation of TOP1
was generated by subcloning of the corresponding BamHI/EcoRI frag-
ment from plasmid pTI-2 [20] (kindly provided by William T. Beck)blished by Elsevier B.V. All rights reserved.
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Fig. 1. Topors promotes the conjugation of multiple SUMO-1
residues to TOP1 in a reconstituted system. (A and B) Sumoylation
of 35S-labeled TOP1 was monitored after addition of 2 lg SUMO-1,
100 ng SAE1/SAE2 and 40 ng UBC9 (Assay-Mix). Where indicated,
an excess amount of UBC9 (500 ng) was used. All reactions without
Topors proteins contained 1 lg of puriﬁed GST protein. (A) Increasing
amounts (0.25, 0.5 and 1.0 lg) of wild type Topors or the RING ﬁnger
deletion mutant (deletion of Topors amino acids 101–143 encompass-
ing the entire RING ﬁnger motif) were added in the form of puriﬁed
GST fusion proteins in the presence of limiting (40 ng) amounts of
UBC9. (B) Incubation in the presence of increasing amounts (0.4, 0.8
and 1.6 lg) of a GST fusion protein harboring Topors amino acids
268–644. (A and B) Arrows indicates the unmodiﬁed form of TOP1,
whereas the regions containing the diverse SUMO-1 modiﬁed TOP1
forms are enclosed within brackets.
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blunted/EcoRI TOP1 restriction fragment was inserted into XhoI-
blunted/EcoRI cut vector pC53+MT [21]. All TOP1 point mutants
were generated by site-directed mutagenesis from the corresponding
parental plasmids with sequential mutagenesis performed for the dou-
ble and triple mutants.
Plasmid pEYFP-SUMO-1 expressing a yellow ﬂuorescent protein
(YFP) tagged SUMO-1 protein, the series of pCATCH-Topors plas-
mids expressing ﬂag-tagged Topors proteins, the pEGFP-Topors plas-
mid expressing a GFP-Topors fusion protein and the pGEX-Topors
plasmids for expression and puriﬁcation of GST-Topors fusion
proteins from bacteria have already been described [15,17]. For pSU-
PER-Topors expressing an siRNA directed against nucleotides 491–
509 of the Topors open reading frame under control of the Pol III
H1-RNA gene promoter, a synthetic double stranded oligonucleotide
(5 0-BglII-overhang-ccc-GGCCTTCGTATAATGGTTC-ttcaagaga-
GAACCATTATACGAAGGCC-tttttggaaa-HindIII-overhang) was
inserted into the BglII/HindIII-sites of vector pSUPER [22].
2.2. In vitro sumoylation assays
35S labeled TOP1 proteins were obtained by coupled in vitro
transcription/translation (Promega) of pBS-Top1 plasmids in rabbit
reticulocyte lysates with T3 RNA polymerase in the presence of
35S-methionine and 35S-cysteine as recommended by the supplier.
Two microliters (of a total of 50 ll) of the translation product were
incubated for 2 h at 30 C in a 20 ll reaction volume (50 mM Tris
pH 7.5, 5 mM MgCl2, 2 mM ATP) containing either 2 lg SUMO-1
(1–97) (Alexis Biochemicals) or 2 lg methylated SUMO-1 (Boston
Biochem), 100 ng E1 (recombinant SAE1/SAE2, Alexis Biochemicals)
and 40 ng UBC9 (Boston Biochem). Puriﬁed GST-Topors proteins [17]
were added in a concentration range of 0.25–1.6 lg. 35S-labeled TOP1
proteins were visualized by autoradiography after SDS–PAGE.
2.3. Cell culture, transient transfections and Western blotting
U2-OS cells maintained in Dulbecco’s modiﬁed Eagle medium sup-
plemented with 10% fetal bovine serum were transfected with the indi-
cated plasmids by the calcium phosphate precipitate technique for 16 h
at 37 C and 5% C02. After medium replacement, cells were incubated
for a further 24 h period. Cells were directly lysed in 200 ll of SDS
sample buﬀer per 60 mm culture dish and proteins were separated by
SDS–PAGE. Immunodetections were performed with a polyclonal
anti-myc antiserum from rabbit (Santa Cruz), a monoclonal mouse
anti-TOP1 antibody (United States Biological) or polyconal anti-
GFP antibody FL from rabbit (Santa Cruz) as indicated.3. Results and discussion
Human Topors has been identiﬁed as cellular interaction
partner of p53 and DNA topoisomerase I (TOP1) [12,13]. It
can function both as ubiquitin [16] and SUMO-1 E3 ligase
[17] for p53. These ﬁndings prompted us to address the ques-
tion whether Topors might also be involved in the sumoylation
of TOP1, which is extensively modiﬁed with SUMO-1 after
treatment of cells with CPT [4].
The inﬂuence of Topors on TOP1 sumoylation was ﬁrst as-
sayed in vitro in a reconstituted system with puriﬁed SUMO-1,
SUMO-1 activating E1 enzyme (SAE1/SAE2), E2 conjugating
enzyme UBC9, and in vitro transcribed/translated TOP1 pro-
tein as substrate. In the absence of Topors, two to three
SUMO-1 modiﬁed forms of TOP1 were observed in the pres-
ence of limiting amounts (40 ng) of UBC9 (Fig. 1A, compare
lane 2 with lane 1). After addition of high amounts of UBC9
(500 ng), the level of unmodiﬁed and monosumoylated TOP1
forms decreased, whereas TOP1 species modiﬁed with up to se-
ven SUMO-1 residues as judged from their migration proper-
ties prevailed (Fig. 1A, lane 3). Reaction mixtures containing
limiting amounts of UBC9 (40 ng) were then supplemented
with increasing amounts of Topors proteins supplied in theform of puriﬁed GST fusion proteins. Both the wild type To-
pors protein and a mutant with a deletion of the N-terminal
RING ﬁnger motif induced the formation of a series of high-
molecular weight TOP1 species modiﬁed with multiple
SUMO-1 residues (Fig. 1A, compare lanes 4–6 and lanes 7–
9, respectively, with lane 2). Strikingly, and in contrast to the
addition of large amounts of UBC9, the ratio of unmodiﬁed
to modiﬁed TOP1 forms was not changed dramatically. We
interpreted these ﬁndings in such a way that Topors is able
to conjugate additional SUMO-1 residues to already sumoylat-
ed TOP1 molecules, either to additional acceptor sites or in
the form of SUMO-1 chains. As for p53, Topors SUMO-1
E3 ligase activity for TOP1 in vitro could be narrowed down
to a central region of the protein encompassing amino acids
268–644. In this particular assay performed with rather large
stochiometric protein amounts, Topors (268/644) not only in-
duced the formation of high-molecular weight SUMO-1-
TOP1 conjugates, but also markedly increased overall TOP1
sumoylation as judged from the decrease in the amount of
unmodiﬁed TOP1 (Fig. 1B). However, this was not observed
in later experiments with lower amounts of the protein (com-
pare Fig. 2). To demonstrate that the high-molecular weight
SUMO-1-TOP1 conjugates were due to the formation of
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Fig. 2. Topors induced polysumoylation of TOP1 point mutants in vitro. (A–D) 35S-labeled wild type or mutant TOP1 proteins were assayed for
sumoylation in the presence of either 2 lg SUMO-1 (A–C) or 2 lg methylated SUMO-1 (right panel in part D), 100 ng SAE1/SAE2 and 40 ng UBC9
(Assay-Mix). Puriﬁed GST fusion proteins of wild type Topors (1.0 lg), the RING ﬁnger deletion mutant (1.0 lg) or the Topors 268/644 deletion
mutant (0.5 lg) were added to the reaction mixture as indicated. The control reactions contained 1.0 lg of puriﬁed GST protein. Arrows indicate the
unmodiﬁed forms of TOP1, whereas the regions containing the SUMO-1 modiﬁed TOP1 forms are enclosed within brackets. (C and D) Where
indicated, reactions were performed in the presence of an excess amount of UBC9 (500 ng) or GST-Topors (268/644) (1.6 lg).
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[11], we point-mutated the three described SUMO-1 acceptor
sites of TOP1 located in the N-terminal part of the protein
at amino acid positions 103, 117 and 153, respectively. Inacti-
vation of the major SUMO-1 acceptor site at lysine residue 117
(Fig. 2A, K117R) resulted in reduced basal sumoylation with
two putative monosumoylated TOP1 forms migrating with
slightly diﬀerent mobilities (marked by asterisks in Fig. 2A),
probably due to modiﬁcation at the two diﬀerent remaining
acceptor sites. Addition of Topors proteins again induced
the accumulation of high-molecular weight conjugates,
although with lower intensity as compared to the wild type
protein (Fig. 2B), corresponding to the lower basal level of
sumoylation. With a TOP1 mutant retaining only the major
sumoylation site (TOP1-K103R/K153R), Topors induced the
accumulation of TOP1 species modiﬁed with multiple
SUMO-1 residues to a similar extent as with the wild type
TOP1 protein (Fig. 2B). Thus these conjugates most likely rep-
resent SUMO-1 chains linked to lysine residue 117. An alterna-
tive explanation, the conjugation of single SUMO-1 moieties
to additional, yet unidentiﬁed, acceptor sites in TOP1, seems
very unlikely in view of the results obtained after additional
point mutation of lysine residue 117. With this triple mutant,only a weak residual sumoylation, detectable exclusively in
the presence of high amounts (500 ng) of UBC or an excess
amount (1.6 lg) of GST-Topors (268/644) (Fig. 2C, lanes 7
and 8), was observed. To further manifest the Topors-medi-
ated formation of SUMO-1 chains on TOP1, sumoylation as-
says with the TOP1 K103/153 mutant were performed in the
presence of methylated SUMO-1 (Fig. 2D). Reductive methyl-
ation of the lysine residues renders SUMO-1 unable to form
chains via lysine linkage with other SUMO-1 molecules.
Whereas enhancement of TOP1 sumoylation by an excess
amount of UBC9 was rather unaﬀected by SUMO-1 methyla-
tion (Fig. 2D, compare lanes 6 and 3), the induction of high-
molecular weight TOP1-SUMO-1 conjugates was abolished
with methylated SUMO-1 (compare lanes 7 and 4). In sum-
mary, the results of the in vitro experiments provided ﬁrm evi-
dence that Topors can induce the formation of SUMO-1
chains on all three TOP1-SUMO-1 acceptor sites.
The inﬂuence of Topors on TOP1 sumoylation in mamma-
lian cells was ﬁrst monitored by cotransfection of the human
osteosarcoma cell line U2-OS with myc-tagged TOP protein,
YFP-tagged SUMO-1 and increasing amounts of Topors
expression constructs. Whereas sumoylation of myc-tagged
TOP1 could not unequivocally be detected in the absence of
E. Hammer et al. / FEBS Letters 581 (2007) 5418–5424 5421SUMO-1 overexpression, YFP or green ﬂuorescent protein
(GFP) tagged SUMO-1 proteins have already been used in a
variety of previous studies examining sumolation of cellular
proteins [17,23] and GFP-SUMO can functionally replace
endogenous SUMO (pmt3) in ﬁssion yeast [24]. In the absence
of ectopic Topors expression, one main additional band corre-
sponding in size to TOP1 modiﬁed with a single YFP-SUMO-
1 entity was observed after YFP-SUMO-1 cotransfection
(Fig. 3A, compare lanes 2 and 3). Several weak high-molecular
weight myc-reactive bands corresponding to TOP1 species
modiﬁed with several YFP-SUMO-1 molecules were also visi-
ble. After cotransfection of increasing amounts of the full-
length wild type Topors protein the intensity of these polysu-
moylated TOP1 bands increased, whereas the amount of the
monosumoylated TOP1 form rather decreased (Fig. 3A, lanesA
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DMSO/PBS for 25 min for the controls.4–6). The in vitro requirement of a central Topors domain for
its SUMO-1 E3 ligase activity towards TOP1 could be con-
ﬁrmed in U2-OS cells with a Topors polypeptide harboring
amino acids 437–574, which induced a comparable polysumoy-
lation of TOP1 as the wild type Topors protein (Fig. 3A, lanes
7–9). With the myc-tagged TOP1 protein, the forced expres-
sion of Topors had a very similar eﬀect as treating the cells
with CPT, which also mainly increased the abundance of the
high-order YFP-SUMO-1 conjugates of TOP1 (Fig. 3B).
In analogy to the in vitro assays, the transfection experiments
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5422 E. Hammer et al. / FEBS Letters 581 (2007) 5418–5424at lysine residues 103 and 153 (Fig. 4B, TOP1-K117R), the cen-
tral Topors domain induced the accumulation of high-order
YFP-SUMO-1 conjugates. YFP-SUMO-1 modiﬁcation in cells
closely mimicked the in vitro experiments also with regard to
the pattern of monosumoylated TOP1 species, with the K117R
mutant showing two bands with slightly diﬀerent mobility’s. Inline with published results [9], the triple mutant K103R/
K117R/K153R was sumoylation-deﬁcient (Fig. 4C).
We then examined the inﬂuence of Topors on sumoylation
of endogenous TOP1 in HeLa cells by cotransfection of To-
pors (437/574) with YFP-SUMO-1, followed by immunoblot
analysis with a TOP1 antibody. Several putative YFP-SUMO
E. Hammer et al. / FEBS Letters 581 (2007) 5418–5424 5423modiﬁed forms of endogenous TOP1 were identiﬁed (Fig. 5A,
indicated by arrows). Some bands with a higher mobility than
the non-modiﬁed TOP1 (marked by asterisks in Fig. 5) were
present in all transfection and some faint signals in the range
of the putative YFP-SUMO-1 modiﬁed forms of TOP1 were
also present in the control without YFP-SUMO-1. However,
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5424 E. Hammer et al. / FEBS Letters 581 (2007) 5418–5424expression was knocked out in HeLa cells transfected with
YFP-SUMO-1 and treated with CPT by means of a cotrans-
fected Topors-siRNA expression construct. The selected To-
pors-siRNA eﬃciently downregulated Topors expression as
monitored in parallel by cotransfection with a GFP-tagged To-
pors construct (Fig. 5C). Whereas the high-order YFP-
SUMO-1 modiﬁed forms of endogenous TOP1 were enhanced
after treatment with CPT (Fig. 5B, compare lanes 2 and 3), this
eﬀect was eﬃciently repressed by delivery of the Topors-siR-
NA. In contrast, knockdown of Topors seems to have only lit-
tle eﬀect on mono- and di-sumoylation of Top1. Therefore it
seems that Topors is not involved in the initial sumoylation
of Top1 after CPT treatment, which probably involves a
SUMO ligase other than Topors, but that the role of Topors
is to facilitate chain formation on already sumoylated lysines.
In conclusion, Topors induced accumulation of high-order
SUMO-1 conjugates of TOP1 did not depend on the presence
of multiple lysine acceptor within the TOP1 sequence, neither
in the reconstituted nor in the cellular system, strongly arguing
for the formation of SUMO-1 chains. The apparently larger
number of SUMO-1 molecules conjugated to individual
TOP1 molecules in the reconstituted in vitro system as com-
pared to the cellular system may be due to the presence of
SUMO-1 speciﬁc isopeptidases in the later system. For the
yeast Smt3/SUMO isopeptidase Ulp2p, a function in the edit-
ing of the SUMO chains has been demonstrated and accumu-
lation of SUMO chains in Ulp2p negative strains induces cell
death and correlates with increased sensitivity to hydroxy-ura-
cil (HU) [25]. These eﬀects are enhanced in the presence of
TOP1 [26], implying TOP1 as a major target for SUMO chain
formation in yeast. TOP1 sumoylation enhances CPT induced
apoptosis in human cells [27] and Topors has also been impli-
cated in cell cycle arrest and induction of apoptosis in mamma-
lian cells [28,29]. Of note, Topors is both induced [28] and
relocated from PML nuclear bodies to the nucleoplasm [14]
after CPT treatment. Further studies will help to clarify the
role of Topors induced formation of SUMO-1 chains on
TOP1 in CPT induced apoptosis.
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